Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.

You may also be interested in...

Janssen R&D Unveils Three New Research Platforms

With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.

Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites

Despite ongoing compliance probes, decelerating growth and continuing price pressure, Merck KGAA and Johnson & Johnson unveil bold localization plans in China with a fresh investment worth millions. They see the need to support essential drug supply, introduce new products and accelerate product registration in China.

Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals

Two high-profile pipeline setbacks over the past six months have prompted a wholesale strategic rethink at Austria's Intercell AG, one of the few remaining publicly quoted vaccine companies in Europe.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts